Isabel M. Barceló

WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent “β-Lactam Enhancer” Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones

Bartolomé Moyá, Isabel M. Barceló, Sachin Bhagwat et al. · Antimicrobial Agents and Chemotherapy · 2017 · 126 citations

Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates

Bartolomé Moyá, Isabel M. Barceló, Sachin Bhagwat et al. · Antimicrobial Agents and Chemotherapy · 2017 · 72 citations · Full text

<i>In Vitro</i> and <i>In Vivo</i> Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae

Bartolomé Moyá, Isabel M. Barceló, Gabriel Cabot et al. · Antimicrobial Agents and Chemotherapy · 2019 · 46 citations · Full text

<i>In vitro</i>evolution of cefepime/zidebactam (WCK 5222) resistance in<i>Pseudomonas aeruginosa</i>: dynamics, mechanisms, fitness trade-off and impact on<i>in vivo</i>efficacy

Isabel M. Barceló, Gabriel Cabot, Snehal Palwe et al. · Journal of Antimicrobial Chemotherapy · 2021 · 29 citations

In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wall–Targeting Immunity

Gabriel Torrens, Irina Sánchez-Diener, Elena Jordana‐Lluch et al. · The Journal of Infectious Diseases · 2019 · 16 citations